Neutropenia clinical presentation

The epidemiology, clinical presentation, and treatment of alveolar echinococcosis of the liver have been described in French patients followed between 1972 and 1993 (5). From 1982 benzimidazoles were used. Of 117 patients, 72 took either albendazole or mebendazole for 4—134 months. The most common adverse effects were an increase in alanine transaminase activity to more than five times the top of the reference range (in six patients taking albendazole and in three taking mebendazole). Neutropenia (leukocyte count below 1.0 x 10 /1) occurred in two patients taking albendazole. Alopecia occurred in four patients taking mebendazole. Minor adverse effects of albendazole included malaise, anorexia, and digestive intolerance in one patient each. In 13 patients treatment had to be withdrawn because of adverse effects n —10) or non-adherence to therapy (n = 3). 

In preliminary clinical trials, 2 of 2,796 mirtazapine-treated patients developed agranulocytosis, and 1 developed severe neutropenia. All 3 patients recovered after medication discontinuation, and other possible etiologies were present in at least 1 of these individuals. Thirteen patients with pretreatment neutropenia did develop more severe neutropenia or agranulocytosis. Postmarketing evaluation to date has not established a causal relation between mirtazapine and agranulocytosis. Routine laboratory monitoring is not currently recommended. 

Despite its powerful anticancer effeets, trabeetedin presents serious adverse event s [23]. In phase I and II clinical trials, the administration of trabectedin eaused dose-dependent reversible myelosuppression [24]. Neutropenia is another dose-dependent side effect [25]. It has also been reported that trabectedin induces hepatotoxicity in patients by increasing serum levels of transaminases, bilirubin and alkaline phosphatase [26] hepatotoxicity has been... 

In several instances severe bone marrow depression occurred, characterized by neutropenia and thrombocytopenia. The clinical chemistry profile of these cases revealed hypocholesterolemia, hyperuricemia, and hypoproteinemia. In a few cases, slight disturbance of liver function was found with mild elevations of aminotransferases. In male subjects, azoospermia or abnormal spermatozoa and reduced motility of spermatozoa were observed. Some cases presented with postexposure lacrimation, hyperemia, and edema of the conjunctiva. There were instances of protracted reduction in visual capacity and reports of retinal abnormalities [45]. Lymphocytes from exposed subjects showed a considerable number of chromosomal aberrations [46,47]. 

Up to the end of 1995, many results of phase II clinical studies on CPT-11 and topotecan administered intravenously have been presented and summarized [183, 184, 187,188]. In phase II studies of CPT-11 against solid tumours, the most popular dosage schedules were 100 mg/m /day once weekly or 150 mg/m /day once every 2 weeks in Japan, 125 mg/m /day once weekly in U.S.A., and 350 mg/m /day once every 3 weeks in Europe. On the other hand, topotecan was infused for 30 min at doses of 1.25-2.0 (dominantly 1.5) mg/m /day once for 5 consecutive days every 3 weeks. Usually, the dose-limiting toxicity of CPT-11 is myelosuppression (mainly neutropenia)... 

A second lead HPMA copolymer-platinate (AP5346) has been identified with a similar Gly-Phe-Leu-Gly-aminomalonate side chain, but in this case terminating in a 1,2-diaminocyclohexyl (DACH) palatinate (Fig. 8). hi Phase 1 clinical trial, it was administered as intravenous infusion of 80-1280 mg Pt/m once a week in 28-day cycle to patients with a broad cross-section of tumour types. Out of the 12 evaluable patients, one demonstrated a partial response. Dose hmiting toxicity was neutropenia but also nausea, vomiting, asthenia, fatigue and diarrhoea were observed (as presented in October 2004 at the 16th... 

---